
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5177552/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clinical Gastroenterology and Hepatology, 2022, 20, 9-18.	4.4	58
2	Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort. Clinical Gastroenterology and Hepatology, 2022, 20, 2393-2395.e4.	4.4	21
3	Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARCET-NASH Study. Clinical Gastroenterology and Hepatology, 2022, 20, 458-460.e4.	4.4	21
4	Impact of a Pilot Structured Mobile Technology Based Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2022, 67, 481-491.	2.3	11
5	Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Digestive Diseases and Sciences, 2022, 67, 2637-2645.	2.3	4
6	Disease Knowledge, Health-Related Quality of Life, and Lifestyle Behavior Change in Patients with Nonalcoholic Fatty Liver Disease: Impact of an Educational Intervention. Digestive Diseases and Sciences, 2022, 67, 2123-2133.	2.3	8
7	Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications. Digestive Diseases and Sciences, 2022, 67, 3623-3631.	2.3	12
8	Incidence and prediction of HBsAg seroclearance in a prospective multiâ€ethnic HBeAgâ€negative chronic hepatitis B cohort. Hepatology, 2022, 75, 709-723.	7.3	13
9	Reply. Hepatology, 2022, 75, 761-763.	7.3	Ο
10	Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology, 2022, 75, 1257-1274.	7.3	26
11	A Dualâ€Filtration System for Single ell Sequencing of Circulating Tumor Cells and Clusters in HCC. Hepatology Communications, 2022, 6, 1482-1491.	4.3	6
12	Viscoelastic Testing Prior to Non-surgical Procedures Reduces Blood Product Use Without Increasing Bleeding Risk in Cirrhosis. Digestive Diseases and Sciences, 2022, 67, 5290-5299.	2.3	17
13	A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. Statistics in Medicine, 2022, 41, 2338-2353.	1.6	1
14	Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
15	Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort. Digestive Diseases and Sciences, 2022, 67, 5300-5308.	2.3	7
16	Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Piâ^—MZ genotype. JHEP Reports, 2022, 4, 100483.	4.9	10
17	How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?. Journal of Hepatology, 2022, 76, 1249-1262.	3.7	69
18	Metabolic abnormalities, liver and body fat in American <i>versus</i> Chinese patients with nonâ€alcoholic fatty liver disease. JGH Open, 2022, 6, 519-530.	1.6	2

#	Article	IF	CITATIONS
19	Sustainable and equivalent improvements in symptoms and functional <scp>wellâ€being</scp> following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis CÂinfection: Findings from the randomized <scp>PRIORITIZE</scp> trial. Journal of Viral Hepatitis, 2022, 29, 795-806.	2.0	1
20	Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. Journal of Hepatology, 2022, 77, 1670-1689.	3.7	26
21	Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Supportive Care in Cancer, 2021, 29, 97-105.	2.2	0
22	Patient Knowledge, Beliefs and Barriers to Hepatitis B Care: Results of a Multicenter, Multiethnic Patient Survey. Digestive Diseases and Sciences, 2021, 66, 434-441.	2.3	11
23	Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 996-1008.e6.	4.4	33
24	Social Support Does Not Modify the Risk of Readmission for Patients with Decompensated Cirrhosis. Digestive Diseases and Sciences, 2021, 66, 1855-1861.	2.3	2
25	New Therapeutics for Hepatitis B: The Road to Cure. Annual Review of Medicine, 2021, 72, 93-105.	12.2	38
26	Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis. Hepatology, 2021, 73, 2429-2440.	7.3	21
27	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology, 2021, 73, 2124-2140.	7.3	23
28	Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease. Digestive Diseases, 2021, 39, 247-257.	1.9	11
29	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. Hepatology, 2021, 73, 1637-1651.	7.3	11
30	Patientâ€reported outcomes 12Âmonths after hepatitis C treatment with directâ€acting antivirals: Results from the PROP UP study. Liver International, 2021, 41, 692-704.	3.9	11
31	Bariatric surgery and the risk of alcoholâ€related cirrhosis and alcohol misuse. Liver International, 2021, 41, 1012-1019.	3.9	22
32	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGETâ€NASH Study. Hepatology Communications, 2021, 5, 938-946.	4.3	21
33	Hepatitis B reactivation after chemoimmunotherapy: screen before treatment. Lancet, The, 2021, 397, 510.	13.7	4
34	The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. Hepatology, 2021, 74, 2813-2823.	7.3	4
35	SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight, 2021, 6, .	5.0	72
36	Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. JCI Insight, 2021, 6, .	5.0	15

#	Article	IF	CITATIONS
37	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreignâ€Born Persons Living in the United States. Hepatology, 2021, 74, 607-626.	7.3	64
38	Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study. BMJ Open Gastroenterology, 2021, 8, e000634.	2.7	15
39	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584.	1.3	91
40	Applying Administrative Dataâ€Based Coding Algorithms for Frailty in Patients With Cirrhosis. Liver Transplantation, 2021, 27, 1401-1411.	2.4	4
41	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology, 2021, 74, 2952-2964.	7.3	7
42	Microbiome therapeutics for hepatic encephalopathy. Journal of Hepatology, 2021, 75, 1452-1464.	3.7	37
43	Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2021, 54, 890-901.	3.7	65
44	Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology, 2021, 74, 2395-2409.	7.3	36
45	Endpoints and New Options for Treatment of Chronic Hepatitis D. Hepatology, 2021, 74, 3479-3485.	7.3	26
46	Strategies to Improve Video Visit Use in Persons With Liver Disease. Gastroenterology, 2021, 161, 1080-1084.e2.	1.3	6
47	Should Treatment Indications for Chronic Hepatitis B Be Expanded?. Clinical Gastroenterology and Hepatology, 2021, 19, 2006-2014.	4.4	45
48	Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic. Journal of Substance Abuse Treatment, 2021, 130, 108396.	2.8	35
49	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1472-1480.	3.7	10
50	Prevalence of Viremic Hepatitis C Virus Infection by Age, Race/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999–2016. Journal of Infectious Diseases, 2020, 221, 408-418.	4.0	19
51	The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. Hepatology, 2020, 71, 225-234.	7.3	40
52	Chronic Hepatitis B Prevalence Among Foreignâ€Born and U.S.â€Born Adults in the United States, 1999â€2016. Hepatology, 2020, 71, 431-443.	7.3	82
53	Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002–2018: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2020, 65, 1539-1548.	2.3	26
54	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. Journal of General Internal Medicine, 2020, 35, 1011-1020.	2.6	16

#	Article	IF	CITATIONS
55	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatology Communications, 2020, 4, 8-20.	4.3	43
56	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRSÂCO13 HEPAVIH)― Journal of Hepatology, 2020, 72, 592-593.	3.7	0
57	Medically tailored meals for the management of symptomatic ascites: the SALTYFOOD pilot randomized clinical trial. Gastroenterology Report, 2020, 8, 453-456.	1.3	4
58	Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. Scientific Reports, 2020, 10, 20922.	3.3	19
59	Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis. American Journal of Gastroenterology, 2020, 115, 2017-2025.	0.4	40
60	Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C. JHEP Reports, 2020, 2, 100136.	4.9	4
61	Clinical Research in Hepatology in the COVIDâ€19 Pandemic and Postâ€Pandemic Era: Challenges and the Need for Innovation. Hepatology, 2020, 72, 1819-1837.	7.3	17
62	Progress towards elimination goals for viral hepatitis. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 533-542.	17.8	118
63	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. Clinical and Translational Gastroenterology, 2020, 11, e00196.	2.5	15
64	DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficienct Virus Co-infection. Clinical Infectious Diseases, 2020, 73, e184-e190.	5.8	13
65	Prevalence and clinical features of patients with concurrent HBsAg and antiâ€HBs: Evaluation of the hepatitis B research network cohort. Journal of Viral Hepatitis, 2020, 27, 922-931.	2.0	10
66	Coronavirus Disease 2019 (COVID-19) Clinical Trial Oversight at a Major Academic Medical Center: Approach of Michigan Medicine. Clinical Infectious Diseases, 2020, 71, 2187-2190.	5.8	16
67	Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America. Annals of Hepatology, 2020, 19, 437-445.	1.5	6
68	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. The Lancet Gastroenterology and Hepatology, 2020, 5, 406-417.	8.1	64
69	Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Clinical Gastroenterology and Hepatology, 2020, 18, 2879-2902.e9.	4.4	81
70	Acceptance and use of a smartphone application in cirrhosis. Liver International, 2020, 40, 1556-1563.	3.9	32
71	Biomarkers for the Early Detection of Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2495-2503.	2.5	67
72	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. Journal of Hepatology, 2020, 73, 540-548.	3.7	85

#	Article	IF	CITATIONS
73	A risk–benefit framework for human research during the COVID-19 pandemic. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27749-27753.	7.1	11
74	USPSTF 2020 Hepatitis B Screening Recommendation. JAMA - Journal of the American Medical Association, 2020, 324, 2380.	7.4	0
75	Entecavir and Peginterferon Alfaâ€2a in Adults With Hepatitis B e Antigen–Positive Immuneâ€Tolerant Chronic Hepatitis B Virus Infection. Hepatology, 2019, 69, 2338-2348.	7.3	37
76	Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials. Clinics in Liver Disease, 2019, 23, 401-416.	2.1	41
77	Survey of Nonalcoholic Fatty Liver Disease Knowledge, Nutrition, and Physical Activity Patterns Among the General Public in Beijing, China. Digestive Diseases and Sciences, 2019, 64, 3480-3488.	2.3	9
78	Incidence of and Risk Factors for Hepatic Encephalopathy in a Populationâ€Based Cohort of Americans With Cirrhosis. Hepatology Communications, 2019, 3, 1510-1519.	4.3	66
79	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology, 2019, 157, 1506-1517.e1.	1.3	32
80	Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcoholâ€Associated Cirrhosis. Alcoholism: Clinical and Experimental Research, 2019, 43, 334-341.	2.4	56
81	Design and rationale of a randomized–controlled trial of home-delivered meals for the management of symptomatic ascites: the SALTYFOOD trial. Gastroenterology Report, 2019, 7, 146-149.	1.3	5
82	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. Journal of Hepatology, 2019, 71, 486-497.	3.7	37
83	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341
84	Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B. PLoS Pathogens, 2019, 15, e1007715.	4.7	23
85	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2541-2551.e2.	4.4	28
86	Reply. Hepatology, 2019, 69, 2301-2301.	7.3	0
87	Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis. Hepatology Communications, 2019, 3, 1585-1597.	4.3	8
88	Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. American Journal of Gastroenterology, 2019, 114, 1753-1763.	0.4	17
89	Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. Liver Transplantation, 2019, 25, 369-379.	2.4	40
90	Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 296-307.	3.7	19

#	Article	IF	CITATIONS
91	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology, 2019, 156, 635-646.e9.	1.3	162
92	Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patientâ€Reported Outcomes in Cirrhosis. Hepatology, 2019, 69, 1676-1685.	7.3	55
93	Awareness and Knowledge of Nonalcoholic Fatty Liver Disease Among Office Employees in Beijing, China. Digestive Diseases and Sciences, 2019, 64, 708-717.	2.3	17
94	A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. Digestive Diseases and Sciences, 2019, 64, 358-366.	2.3	7
95	Evaluating longitudinal markers under two-phase study designs. Biostatistics, 2019, 20, 485-498.	1.5	0
96	Dos and Don'ts in the Management of Cirrhosis: A View from the 21st Century. American Journal of Gastroenterology, 2018, 113, 927-931.	0.4	14
97	The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology, 2018, 68, 872-882.	7.3	154
98	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67, 1560-1599.	7.3	2,620
99	Psychometric properties of the <scp>PROMIS</scp> short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Alimentary Pharmacology and Therapeutics, 2018, 47, 1001-1011.	3.7	16
100	Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs. Journal of the American Statistical Association, 2018, 113, 882-892.	3.1	3
101	A Bayesian Screening Approach for Hepatocellular Carcinoma Using Multiple Longitudinal Biomarkers. Biometrics, 2018, 74, 249-259.	1.4	16
102	Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology, 2018, 67, 36-47.	7.3	96
103	Model-free Scoring System for Risk Prediction with Application to Hepatocellular Carcinoma Study. Biometrics, 2018, 74, 239-248.	1.4	3
104	A research agenda for curing chronic hepatitis B virus infection. Hepatology, 2018, 67, 1127-1131.	7.3	70
105	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. Journal of Clinical Oncology, 2018, 36, 959-967.	1.6	18
106	Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. Lancet Haematology,the, 2018, 5, e474-e478.	4.6	20
107	Optimizing medication management for patients with cirrhosis: Evidenceâ€based strategies and their outcomes. Liver International, 2018, 38, 1882-1890.	3.9	21
108	Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis. Journal of Substance Abuse Treatment, 2018, 91, 20-27.	2.8	73

#	Article	IF	CITATIONS
109	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS ONE, 2018, 13, e0196908.	2.5	23
110	Predictors and Barriers to Hepatitis B Screening in a Midwest Suburban Asian Population. Journal of Community Health, 2017, 42, 533-543.	3.8	15
111	Characterization of contrasting features between hepatitis B virus genotype A and genotype D in small envelope protein expression and surface antigen secretion. Virology, 2017, 503, 52-61.	2.4	14
112	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemporary Clinical Trials, 2017, 57, 58-68.	1.8	13
113	Impact of the timing of hepatitis B virus identification and anti–hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer, 2017, 123, 3367-3376.	4.1	13
114	Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. Journal of Viral Hepatitis, 2017, 24, 1032-1042.	2.0	10
115	Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China. Digestive Diseases and Sciences, 2017, 62, 2141-2149.	2.3	4
116	Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA. Digestive Diseases and Sciences, 2017, 62, 3243-3253.	2.3	12
117	Benefits of Direct-Acting Antivirals for Hepatitis C. Annals of Internal Medicine, 2017, 167, 812.	3.9	13
118	The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 731-740.	3.7	21
119	Society Leadership and Diversity: Hail to the Women!. Gastrointestinal Endoscopy, 2017, 86, 413-415.	1.0	2
120	Society Leadership and Diversity: Hail to the Women!. American Journal of Gastroenterology, 2017, 112, 1353-1355.	0.4	3
121	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clinical Infectious Diseases, 2017, 65, 1773-1775.	5.8	11
122	Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemporary Clinical Trials, 2017, 61, 33-38.	1.8	38
123	NAM 2017 report: A national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD's response. Hepatology, 2017, 66, 1020-1022.	7.3	9
124	Improving efficiency in biomarker incremental value evaluation under two-phase designs. Annals of Applied Statistics, 2017, 11, 638-654.	1.1	6
125	Comments on cochrane review on directâ€acting antivirals for hepatitis C. Hepatology, 2017, 66, 1016-1019.	7.3	3
126	Hepatitis B cure: From discovery to regulatory approval. Journal of Hepatology, 2017, 67, 847-861.	3.7	189

#	Article	IF	CITATIONS
127	Interview with American Association for the Study of Liver Diseases president Dr. Anna Lok. Hepatology Communications, 2017, 1, 189-192.	4.3	0
128	Reply. Hepatology, 2017, 66, 679-680.	7.3	0
129	Hepatitis B cure: From discovery to regulatory approval. Hepatology, 2017, 66, 1296-1313.	7.3	235
130	Society Leadership and Diversity: Hail to the Women!. Hepatology, 2017, 66, 686-690.	7.3	3
131	Society Leadership and Diversity: Hail to the Women!. Gastroenterology, 2017, 153, 618-620.	1.3	9
132	Survival and costâ€effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER–Medicare database. Hepatology, 2017, 65, 122-133.	7.3	82
133	Acute Rejection Increases Risk of Graft Failure and Death inÂRecent Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2017, 15, 584-593.e2.	4.4	162
134	Patient Education Improves Patient Knowledge and Acceptance on Antiviral Therapy of Hepatitis C in Rural China. Chinese Medical Journal, 2017, 130, 2750-2751.	2.3	5
135	Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C. PLoS ONE, 2017, 12, e0187344.	2.5	26
136	Recurrent primary sclerosing cholangitis in the Adultâ€ŧoâ€Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients. Liver Transplantation, 2016, 22, 1214-1222.	2.4	51
137	Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. Liver International, 2016, 36, 1595-1603.	3.9	59
138	Reply. Hepatology, 2016, 64, 1824-1825.	7.3	0
139	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and metaâ€analysis. Hepatology, 2016, 63, 284-306.	7.3	414
140	Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. Journal of Hepatology, 2016, 65, 509-516.	3.7	142
141	Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and metaâ€analysis. Hepatology, 2016, 63, 307-318.	7.3	62
142	Hepatitis C Treatment and Barriers to Eradication. Clinical and Translational Gastroenterology, 2016, 7, e193.	2.5	57
143	Letter: lessons from the â€~real-world' entecavir therapy in chronic hepatitis B patients - authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 847-848.	3.7	0
144	Entecavir safety and effectiveness in a national cohort of treatmentâ€naÃ⁻ve chronic hepatitis B patients in the <scp>US</scp> – the <scp>ENUMERATE</scp> study. Alimentary Pharmacology and Therapeutics, 2016, 43, 134-144.	3.7	63

#	Article	IF	CITATIONS
145	Interferon Treatment for Hepatitis B. Clinics in Liver Disease, 2016, 20, 645-665.	2.1	81
146	A Comparative Study of Liver Disease Care in the USA and Urban and Rural China. Digestive Diseases and Sciences, 2016, 61, 2847-2856.	2.3	2
147	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. American Journal of Gastroenterology, 2016, 111, 1297-1304.	0.4	39
148	Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and metaâ€analysis. Hepatology, 2016, 63, 319-333.	7.3	275
149	Primary Care Physician Perspectives on Hepatitis C Management in the Era of Direct-Acting Antiviral Therapy. Digestive Diseases and Sciences, 2016, 61, 3460-3468.	2.3	34
150	Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology, 2016, 150, 684-695.e5.	1.3	178
151	Improved Detection of Hepatocellular Carcinoma by Using aÂLongitudinal Alpha-Fetoprotein Screening Algorithm. Clinical Gastroenterology and Hepatology, 2016, 14, 469-475.e2.	4.4	67
152	Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014. Hepatology International, 2016, 10, 139-146.	4.2	10
153	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	7.3	269
154	Changes in characteristics of hepatitis <scp>C</scp> patients seen in a liver centre in the <scp>U</scp> nited <scp>S</scp> tates during the last decade. Journal of Viral Hepatitis, 2015, 22, 481-488.	2.0	9
155	Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology, 2015, 62, 1364-1374.	7.3	29
156	Preventing Hepatitis B Reactivation Due to Immunosuppressive Drug Treatments. JAMA - Journal of the American Medical Association, 2015, 313, 1617.	7.4	56
157	Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology, 2015, 61, 1832-1841.	7.3	54
158	ls It More Cost-effective for Patients With Chronic Hepatitis B to Have a Trial of Interferon Before Considering Nucleos(t)ide Analogue Therapy?. Clinical Gastroenterology and Hepatology, 2015, 13, 386-389.	4.4	6
159	Recent US Food and Drug Administration warnings on hepatitis B reactivation with immuneâ€suppressing and anticancer drugs: Just the tip of the iceberg?. Hepatology, 2015, 61, 703-711.	7.3	192
160	A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China. Hepatology International, 2015, 9, 58-66.	4.2	13
161	Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. Journal of Hepatology, 2015, 62, S76-S86.	3.7	198
162	Outcomes of Patients With Chronic Hepatitis B Who Do Not Meet Criteria for Antiviral Treatment at Presentation. Clinical Gastroenterology and Hepatology, 2015, 13, 193-201.e1.	4.4	24

#	Article	IF	CITATIONS
163	Personalized treatment of hepatitis B. Clinical and Molecular Hepatology, 2015, 21, 1.	8.9	24
164	Does suppression of HBV replication by antiviral therapy confer the same benefit as host immune control of HBV?. Gut, 2014, 63, 1833-1834.	12.1	3
165	New all-oral HCV therapies for genotype 1: A final good-bye to interferon. Clinical Liver Disease, 2014, 3, 137-140.	2.1	4
166	Diagnostic Challenges of Hepatitis C. JAMA - Journal of the American Medical Association, 2014, 311, 2536.	7.4	5
167	Potential Benefit of Telbivudine on Renal Function Does Not Outweigh Its High Rate of Antiviral Drug Resistance and Other Adverse Effects. Gastroenterology, 2014, 146, 15-19.	1.3	13
168	Impact of New Hepatitis C Treatments in Different Regions of the World. Gastroenterology, 2014, 146, 1145-1150.e4.	1.3	48
169	Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. Journal of Hepatology, 2014, 60, 490-499.	3.7	135
170	Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy. Journal of Oncology Practice, 2014, 10, e167-e174.	2.5	19
171	Viral hepatitis and pregnancy. Clinical Liver Disease, 2014, 4, 55-57.	2.1	2
172	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatology International, 2014, 8, 382-394.	4.2	9
173	Hepatitis B virus infection. Lancet, The, 2014, 384, 2053-2063.	13.7	1,233
174	Management of Hepatitis B: Our Practice and How It Relates to the Guidelines. Clinical Gastroenterology and Hepatology, 2014, 12, 16-26.	4.4	94
175	Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival. Hepatology International, 2013, 7, 990-999.	4.2	13
176	Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?. American Journal of Gastroenterology, 2013, 108, 425-432.	0.4	193
177	Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma. American Journal of Gastroenterology, 2013, 108, 1723-1730.	0.4	233
178	Should Treatment of Hepatitis B Patients Be Based Solely on Liver Fibrosis?. Clinical Gastroenterology and Hepatology, 2013, 11, 1500-1502.	4.4	2
179	Criterios para seleccionar a los pacientes infectados por el VHC que son candidatos al tratamiento antiviral. Clinical Liver Disease, 2013, 2, S20Å-S23Å.	2.1	1
180	Hepatitis B Screening and Vaccination Practices in Asian American Primary Care. Gut and Liver, 2013, 7, 450-457.	2.9	22

#	Article	IF	CITATIONS
181	Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C. American Journal of Gastroenterology, 2012, 107, 64-74.	0.4	100
182	Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. American Journal of Gastroenterology, 2012, 107, 1388-1398.	0.4	14
183	Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable. Annals of Internal Medicine, 2012, 156, 743.	3.9	74
184	Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. New England Journal of Medicine, 2012, 366, 216-224.	27.0	580
185	<scp>YKL</scp> â€40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver International, 2012, 32, 665-674.	3.9	21
186	Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review. Journal of Hepatology, 2012, 57, 196-202.	3.7	152
187	Effectiveness of Hepatitis B Treatment in Clinical Practice. Gastroenterology, 2012, 142, 1360-1368.e1.	1.3	131
188	Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-NaÃ ⁻ ve Patients With Chronic Hepatitis B. Gastroenterology, 2012, 143, 619-628.e1.	1.3	137
189	Issues in selecting HCV-infected candidates for anti-viral treatment. Clinical Liver Disease, 2012, 1, 29-31.	2.1	0
190	Mallory–Denk Bodies Are Associated With Outcomes and Histologic Features in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2011, 9, 902-909.e1.	4.4	22
191	Hepatitis B Virus Core Promoter Mutations Contribute to Hepatocarcinogenesis by Deregulating SKP2 and Its Target, p21. Gastroenterology, 2011, 141, 1412-1421.e5.	1.3	71
192	Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C. Gastroenterology, 2011, 140, 840-849.e1.	1.3	178
193	Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. Journal of Hepatology, 2011, 54, 12-18.	3.7	113
194	Hepatitis B therapy. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 275-284.	17.8	232
195	Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenetics and Genomics, 2011, 21, 851-860.	1.5	18
196	Does Antiviral Therapy Prevent Hepatocellular Carcinoma?. Antiviral Therapy, 2011, 16, 787-795.	1.0	29
197	Clinical outcomes of liver transplantation for HBVâ€related hepatocellular carcinoma: data from the NIH HBV OLT study. Clinical Transplantation, 2011, 25, E152-62.	1.6	13
198	Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology, 2011, 54, 434-442.	7.3	70

#	Article	IF	CITATIONS
199	Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology, 2011, 53, 1854-1863.	7.3	113
200	Reply:. Hepatology, 2011, 54, 373-374.	7.3	0
201	Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology, 2011, 54, 1527-1537.	7.3	27
202	Hepatitis B Virus Genotype C Isolates with Wild-Type Core Promoter Sequence Replicate Less Efficiently than Genotype B Isolates but Possess Higher Virion Secretion Capacity. Journal of Virology, 2011, 85, 10167-10177.	3.4	44
203	Viral Factors and Outcomes of Chronic HBV Infection. American Journal of Gastroenterology, 2011, 106, 93-95.	0.4	24
204	New approaches to optimize treatment responses in chronic hepatitis B. Antiviral Therapy, 2010, 15, 61-68.	1.0	7
205	Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatology International, 2010, 4, 707-715.	4.2	22
206	Hepatitis B Prevalence Among Asian Americans in Michigan: An Assessment to Guide Future Education and Intervention Strategies. Journal of Community Health, 2010, 35, 534-542.	3.8	17
207	Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase?. Hepatology, 2010, 51, 1107-1109.	7.3	2
208	Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 2010, 52, 833-844.	7.3	428
209	Drug Therapy: Tenofovir. Hepatology, 2010, 52, 743-747.	7.3	18
210	Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut, 2010, 59, 1401-1409.	12.1	92
211	New Pharmacologic Therapies in Chronic Hepatitis B. Gastroenterology Clinics of North America, 2010, 39, 659-680.	2.2	1
212	Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial. Clinical Gastroenterology and Hepatology, 2010, 8, 458-462.	4.4	80
213	Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C. Gastroenterology, 2010, 138, 136-146.	1.3	82
214	Des-Î ³ -Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. Gastroenterology, 2010, 138, 493-502.	1.3	524
215	Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. Journal of Hepatology, 2010, 53, 348-356.	3.7	397
216	Overview of the viral hepatitis problem. Journal of Family Practice, 2010, 59, S11-6.	0.2	1

#	Article	IF	CITATIONS
217	What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation?. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 68-69.	1.7	3
218	Do guidelines preclude hepatitis B patients from receiving treatment?. Hepatology, 2009, 49, 700-701.	7.3	5
219	Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology, 2009, 49, 1828-1837.	7.3	51
220	Indications for therapy in hepatitis B. Hepatology, 2009, 49, S129-S137.	7.3	61
221	Reply:. Hepatology, 2009, 50, 658-659.	7.3	0
222	Chronic hepatitis B: Update 2009. Hepatology, 2009, 50, 661-662.	7.3	2,506
223	Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology, 2009, 50, 1750-1755.	7.3	195
224	Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transplantation, 2009, 15, 1010-1020.	2.4	26
225	Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatology International, 2009, 3, 582-586.	4.2	86
226	Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. Journal of Hepatology, 2009, 50, 42-48.	3.7	46
227	Evolution of nucleoside/tide analogues for hepatitis B: Is the ideal drug here yet?. Journal of Hepatology, 2009, 51, 416-418.	3.7	5
228	Hepatitis B virus variants. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 453-462.	17.8	147
229	Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. Gastroenterology, 2009, 136, 138-148.	1.3	570
230	Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Gastroenterology, 2009, 137, 549-557.	1.3	125
231	Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transplantation, 2008, 14, 534-540.	2.4	80
232	Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transplantation, 2008, 14, 1420-1427.	2.4	11
233	How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transplantation, 2008, 14, S8-S14.	2.4	20
234	Should Liver Biopsies Be Performed on All Hepatitis B Carriers?. Gastroenterology, 2008, 135, 1802.	1.3	3

#	Article	IF	CITATIONS
235	Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. Journal of Hepatology, 2008, 48, 391-398.	3.7	128
236	Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: Which method should be used?. Journal of Hepatology, 2008, 48, 892-894.	3.7	7
237	Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2008, 100, 1121-1123.	6.3	16
238	Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. New England Journal of Medicine, 2008, 359, 2429-2441.	27.0	445
239	Management of viral resistance in the therapy of chronic hepatitis B. Gastroenterology and Hepatology, 2008, 4, 849-51.	0.1	0
240	A Genotype-Independent Real-Time PCR Assay for Quantification of Hepatitis B Virus DNA. Journal of Clinical Microbiology, 2007, 45, 553-558.	3.9	50
241	When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?. Annals of Internal Medicine, 2007, 147, 62.	3.9	13
242	Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: A comparison of AFP, DCP, and AFP-L31. Cancer Biomarkers, 2007, 3, 79-87.	1.7	131
243	Chronic hepatitis B. Hepatology, 2007, 45, 507-539.	7.3	2,422
244	Outcomes of Patients With Hepatitis B Who Developed Antiviral Resistance While on the Liver Transplant Waiting List. Clinical Gastroenterology and Hepatology, 2007, 5, 1454-1461.	4.4	20
245	Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Clinical Gastroenterology and Hepatology, 2007, 5, 245-254.	4.4	46
246	Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. Gastroenterology, 2007, 133, 1437-1444.	1.3	324
247	Management of hepatitis B: Summary of a clinical research workshop. Hepatology, 2007, 45, 1056-1075.	7.3	568
248	Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology, 2007, 46, 254-265.	7.3	418
249	Corrections to AASLD guidelines on chronic hepatitis B. Hepatology, 2007, 45, 1347-1347.	7.3	22
250	Reply:. Hepatology, 2007, 46, 607-607.	7.3	0
251	Reply:. Hepatology, 2007, 46, 280-280.	7.3	9
252	Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transplantation, 2007, 13, 334-342.	2.4	33

#	Article	IF	CITATIONS
253	Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transplantation, 2007, 13, 323-326.	2.4	22
254	Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transplantation, 2007, 13, 374-381.	2.4	103
255	Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transplantation, 2007, 13, 1100-1108.	2.4	92
256	Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation, 2007, 13, 1137-1144.	2.4	68
257	Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?. Journal of Viral Hepatitis, 2007, 14, 29-36.	2.0	63
258	Virologic response and resistance to adefovir in patients with chronic hepatitis B. Journal of Hepatology, 2006, 44, 283-290.	3.7	337
259	Update on viral hepatitis: 2005. Current Opinion in Internal Medicine, 2006, 5, 392-398.	1.5	9
260	Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver International, 2006, 26, 796-804.	3.9	10
261	Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology, 2006, 44, 703-712.	7.3	238
262	Tenofovir disoproxil fumarate: Role in hepatitis B treatment. Hepatology, 2006, 44, 309-313.	7.3	27
263	Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology, 2006, 44, 1675-1684.	7.3	145
264	Antiviral options for the treatment of chronic hepatitis B. Journal of Antimicrobial Chemotherapy, 2006, 57, 1030-1034.	3.0	42
265	Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. New England Journal of Medicine, 2006, 354, 1011-1020.	27.0	1,118
266	Treatment of Hepatitis B. Archives of Internal Medicine, 2006, 166, 9.	3.8	22
267	Sensitive Line Probe Assay That Simultaneously Detects Mutations Conveying Resistance to Lamivudine and Adefovir. Journal of Clinical Microbiology, 2006, 44, 1094-1097.	3.9	56
268	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine, 2006, 354, 1001-1010.	27.0	1,345
269	Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology, 2005, 42, 282-292.	7.3	299
270	Reply:. Hepatology, 2005, 42, 739-740.	7.3	4

#	Article	IF	CITATIONS
271	Liver transplantation for patients with lamivudine-resistant HBV: What is the optimal prophylactic strategy?. Liver Transplantation, 2005, 11, 490-493.	2.4	10
272	Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. Journal of Hepatology, 2005, 42, 218-224.	3.7	461
273	Management of patients with hepatitis B virus-induced cirrhosis. Journal of Hepatology, 2005, 42, S54-S64.	3.7	28
274	Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. Journal of Hepatology, 2005, 43, 434-441.	3.7	310
275	Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. Journal of Hepatology, 2005, 43, 937-943.	3.7	207
276	New Treatment of Chronic Hepatitis B. Seminars in Liver Disease, 2004, 24, 77-82.	3.6	78
277	Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Contemporary Clinical Trials, 2004, 25, 472-492.	1.9	160
278	Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection?. Hepatology, 2004, 40, 790-792.	7.3	71
279	Chronic hepatitis B: Update of recommendations. Hepatology, 2004, 39, 857-861.	7.3	473
280	Reply:. Hepatology, 2004, 39, 863-863.	7.3	1
281	Effectiveness of interferon ?-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clinical Gastroenterology and Hepatology, 2004, 2, 425-431.	4.4	23
282	Treatment of chronic hepatitis B: Who to treat, what to use, and for how long?. Clinical Gastroenterology and Hepatology, 2004, 2, 839-848.	4.4	27
283	Occult hepatitis B virus infection in patients with hepatocellular carcinoma: innocent bystander, cofactor, or culprit?. Gastroenterology, 2004, 126, 347-350.	1.3	33
284	Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3â~†. Gastroenterology, 2004, 126, 1015-1023.	1.3	436
285	Prevention of hepatitis B virus–related hepatocellular carcinoma. Gastroenterology, 2004, 127, S303-S309.	1.3	133
286	Drug Insight: nucleoside and nucleotide analog inhibitors for hepatitis B. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 90-97.	1.7	21
287	Viral hepatitis in 2003. Current Opinion in Gastroenterology, 2004, 20, 241-247.	2.3	8
288	Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection?. Hepatology, 2004, 40, 790-792.	7.3	137

#	Article	IF	CITATIONS
289	Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology, 2003, 37, 1114-1121.	7.3	331
290	Prevalence of HBV precore/core promoter variants in the United States. Hepatology, 2003, 38, 619-628.	7.3	185
291	The Role of Optimism/Pessimism in HRQOL in Chronic Hepatitis C Patients. Journal of Clinical Psychology in Medical Settings, 2003, 10, 41-49.	1.4	12
292	Natural history of hepatitis b and outcomes after liver transplantation. Clinics in Liver Disease, 2003, 7, 521-536.	2.1	23
293	Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology, 2003, 125, 444-451.	1.3	306
294	Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003, 125, 1714-1722.	1.3	724
295	Identification and Management of Hepatitis C Patients in Primary Care Clinics. American Journal of Gastroenterology, 2003, 98, 639-644.	0.4	71
296	Rapid and Sensitive Assays for Determination of Hepatitis B Virus (HBV) Genotypes and Detection of HBV Precore and Core Promoter Variants. Journal of Clinical Microbiology, 2003, 41, 3699-3705.	3.9	93
297	Hepatitis B: Progress in the Last Decade. Seminars in Liver Disease, 2003, 23, 001-004.	3.6	23
298	Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay. Journal of Clinical Microbiology, 2002, 40, 3729-3734.	3.9	146
299	Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology, 2002, 122, 1756-1762.	1.3	433
300	HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology, 2002, 36, 1425-1430.	7.3	157
301	NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States. Hepatology, 2002, 36, 1349-1354.	7.3	296
302	Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology, 2002, 36, 1408-1415.	7.3	125
303	HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology, 2002, 36, 1425-1430.	7.3	197
304	Noninvasive monitoring of patients with chronic hepatitis C. Hepatology, 2002, 36, S57-S64.	7.3	118
305	Treatment of hepatitis B. Journal of Gastroenterology, 2002, 37, 771-778.	5.1	39
306	Clinical significance of hepatitis B virus genotypes. Hepatology, 2002, 35, 1274-1276.	7.3	211

#	Article	IF	CITATIONS
307	Noninvasive monitoring of patients with chronic hepatitis C. Hepatology, 2002, 36, s57-s64.	7.3	114
308	Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transplantation, 2002, 8, 433-439.	2.4	119
309	Prevention of recurrent hepatitis B post–liver transplantation. Liver Transplantation, 2002, 8, S67-S73.	2.4	76
310	Combination of HBIG and lamivudine-resistant mutations: A formula for trouble?. Liver Transplantation, 2002, 8, 1082-1084.	2.4	3
311	NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology, 2002, 36, 1349-1354.	7.3	413
312	Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology, 2002, 36, 1408-1415.	7.3	189
313	Management of hepatitis B: 2000—Summary of a workshop. Gastroenterology, 2001, 120, 1828-1853.	1.3	748
314	Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. Journal of Viral Hepatitis, 2001, 8, 377-383.	2.0	99
315	Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology, 2001, 33, 751-757.	7.3	351
316	Hepatitis B infection in patients with acute liver failure in the United States. Hepatology, 2001, 33, 972-976.	7.3	43
317	Occult hepatitis B virus infection: A hidden menace?. Hepatology, 2001, 34, 204-206.	7.3	137
318	Liver transplantation in patients with hepatitis B virus infection: Outcome in asian versus white patients. Hepatology, 2001, 34, 126-132.	7.3	20
319	Chronic hepatitis B. Hepatology, 2001, 34, 1225-1241.	7.3	730
320	Outcome of liver transplantation for hepatitis B: Report of a single center's experience. Liver Transplantation, 2001, 7, 724-731.	2.4	13
321	Hepatitis B e antigen-negative chronic hepatitis b in Hong Kong. Hepatology, 2000, 31, 763-768.	7.3	190
322	À La Carte Interferon for Hepatitis C?. Hepatology, 2000, 32, 678-679.	7.3	9
323	Evolution of Hepatitis B Virus Polymerase Gene Mutations in Hepatitis B e Antigen–Negative Patients Receiving Lamivudine Therapy. Hepatology, 2000, 32, 1145-1153.	7.3	182
324	Hepatitis B infection: Pathogenesis and management. Journal of Hepatology, 2000, 32, 89-97.	3.7	125

Αννά Γοκ

#	Article	IF	CITATIONS
325	Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. Journal of Viral Hepatitis, 1999, 6, 183-194.	2.0	46
326	Different hepatitis b virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology, 1999, 29, 976-984.	7.3	251
327	Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology, 1999, 30, 794-800.	7.3	41
328	Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology, 1998, 27, 213-222.	7.3	324
329	Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. Journal of Viral Hepatitis, 1998, 5, 171-178.	2.0	39
330	Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology, 1997, 25, 1497-1501.	7.3	161
331	Diagnosis of hepatitis C. Hepatology, 1997, 26, 48S-56S.	7.3	73
332	Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology, 1995, 21, 19-24.	7.3	61
333	Pathogenic role of hepatitis B virus in hepatitis B surface antigen—negative decompensated cirrhosis. Hepatology, 1995, 22, 25-29.	7.3	54
334	A young man with a solitary hepatic mass. Hepatology, 1995, 22, 655-659.	7.3	3
335	Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology, 1995, 21, 19-24.	7.3	49
336	A young woman with cirrhosis: Autoimmune hepatitis vs. α1-antitrypsin deficiency. Hepatology, 1994, 19, 1302-1306.	7.3	4
337	Treatment of chronic hepatitis B. Journal of Viral Hepatitis, 1994, 1, 105-124.	2.0	64
338	Epidemiology and serologic diagnosis of hepatitis E. Journal of Hepatology, 1994, 20, 567-569.	3.7	18
339	Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4077-4081.	7.1	364
340	A young woman with cirrhosis: autoimmune hepatitis vs. alpha 1-antitrypsin deficiency. Hepatology, 1994, 19, 1302-6.	7.3	1
341	A young woman with chronic hepatitis. Hepatology, 1993, 17, 739-745.	7.3	3
342	Longitudinal study of hepatitis C viremia in chronic hepatitis C. Journal of Medical Virology, 1993, 41, 338-342.	5.0	12

#	Article	IF	CITATIONS
343	Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology, 1993, 105, 1833-1838.	1.3	200
344	Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology, 1993, 18, 497-502.	7.3	39
345	Natural History and Control of Perinatally Acquired Hepatitis B Virus Infection. Digestive Diseases, 1992, 10, 46-52.	1.9	90
346	A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology, 1992, 102, 2091-2097.	1.3	241
347	Seroepidemiological survey of hepatitis E in Hong Kong by recombinant-based enzyme immunoassays. Lancet, The, 1992, 340, 1205-1208.	13.7	135
348	Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. Journal of Hepatology, 1992, 14, 332-334.	3.7	9
349	Interferon treatment for hepatitis B-associated membranous glomerulonephritis in two Chinese children. Pediatric Nephrology, 1992, 6, 417-420.	1.7	21
350	Hepatitis C viremia in patients with hepatitis C virus infection. Hepatology, 1992, 15, 1007-1012.	7.3	49
351	Alphaâ€interferon therapy for chronic hepatitis B virus infection in children and Oriental patients. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 15-17.	2.8	15
352	Interferon alfa therapy in patients with chronic hepatitis B virus infection. Gastroenterology, 1991, 100, 756-761.	1.3	42
353	Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology, 1991, 100, 182-188.	1.3	796
354	Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus–related chronic liver diseases. Hepatology, 1991, 13, 834-837.	7.3	17
355	Overestimation of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera. Hepatology, 1991, 14, 756-762.	7.3	43
356	A randomised controlled trial of recombinant interferon-Î ³ in chinese patients with chronic hepatitis B virus infection. Journal of Medical Virology, 1991, 34, 184-187.	5.0	35
357	Current seroepidemiology of hepatitis A in Hong Kong. Journal of Medical Virology, 1991, 34, 191-193.	5.0	37
358	Hepatitis B virus replication in chinese patients with hepatocellular carcinoma. Hepatology, 1990, 12, 582-588.	7.3	14
359	Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology, 1990, 12, 1266-1270.	7.3	82
360	Hepatitis B infection in patients with lymphomas. Hematological Oncology, 1990, 8, 261-270.	1.7	119

#	Article	IF	CITATIONS
361	α-Interferon treatment in Chinese patients with chronic hepatitis B. Journal of Hepatology, 1990, 11, S121-S125.	3.7	21
362	Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Journal of Hepatology, 1990, 10, 29-34.	3.7	245
363	α-fetoprotein monitoring in chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma. Hepatology, 1989, 9, 110-115.	7.3	183
364	Synergism of chronic alcoholism and hepatitis B infection in liver disease. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 11-16.	2.8	14
365	Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. Hepatology, 1988, 8, 766-770.	7.3	147
366	A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive chinese children. Hepatology, 1988, 8, 1130-1133.	7.3	189
367	LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT $\hat{1}\pm 2$ -INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION. Lancet, The, 1988, 332, 298-302.	13.7	169
368	Prochlorperazine-induced chronic cholestasis. Journal of Hepatology, 1988, 6, 369-373.	3.7	23
369	Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology, 1987, 92, 1839-1843.	1.3	320
370	PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN. Lancet, The, 1987, 330, 877-880.	13.7	164
371	Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection Gut, 1984, 25, 1283-1287.	12.1	108